Literature DB >> 6486559

The effect of maintenance theophylline therapy on lung work in severe chronic obstructive pulmonary disease while standing and walking.

J W Jenne, J R Siever, W S Druz, J V Solano, S M Cohen, J T Sharp.   

Abstract

There is controversy whether routine use of theophylline is warranted in chronic obstructive pulmonary disease (COPD). Effects on spirometry are minimal, and subjective relief is difficult to document. Therefore, we undertook to study the pulmonary effects of theophyline using a functional approach, namely, its effects on the lung mechanics of a standing or walking patient. In a double blind, placebo controlled crossover study, 400 mg of slow-release theophylline (TheoDur) were given twice a day in 13 trials to 10 patients with severe COPD. Lung mechanics were calculated on a breath-by-breath basis by a pulmonary mechanics computer from esophageal pressures and flow. Expired volumes were simultaneously collected. Spirometry was then performed. On the placebo limb, the spirometric response to 0.5 mg terbutaline given subcutaneously was compared with the theophylline response. At a mean serum theophylline level of 12.3 micrograms/ml, theophylline produced in the entire group a mean reduction in the work of breathing done on the lung (WL) of 16% (p less than 0.002) while walking, but a significant effect while standing was not detected. During both walking and standing, the mean reduction in lung resistance (RL) was 15 to 16% (p less than 0.002). Minute volume (VE) was increased at borderline significance, with a mean reduction while walking of 19% in the ratio of WL to VE (p less than 0.002). In the individual patient, changes in WL were influenced more by changes in VE than by changes in RL; in fact, changes in WL correlated best with changes in the product of (VE)2 and RL. Theophylline produced a mean increase of 15% in forced expiratory volume in one second (FEV1) and 16% in forced vital capacity (FVC).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6486559     DOI: 10.1164/arrd.1984.130.4.600

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

Review 1.  Long acting beta(2) agonists and theophylline in stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner; M G Matera
Journal:  Thorax       Date:  1999-08       Impact factor: 9.139

Review 2.  Management of asthma and chronic airflow limitation: are methylxanthines obsolete?

Authors:  M T Newhouse; A Lam
Journal:  Lung       Date:  1990       Impact factor: 2.584

Review 3.  Should bronchodilators be combined in chronic bronchitis and emphysema?

Authors:  D C Flenley
Journal:  Br Med J (Clin Res Ed)       Date:  1987-11-07

4.  Bronchodilators in COPD.

Authors:  J C Yernault; A Noseda
Journal:  Thorax       Date:  1994-11       Impact factor: 9.139

5.  Slow release theophyllines and chronic bronchitis.

Authors:  G M Cochrane
Journal:  Br Med J (Clin Res Ed)       Date:  1984-12-15

Review 6.  Long-acting beta2 agonists in the management of stable chronic obstructive pulmonary disease.

Authors:  M Cazzola; C F Donner
Journal:  Drugs       Date:  2000-08       Impact factor: 9.546

Review 7.  The pharmacological approach to the elderly COPD patient.

Authors:  Timothy E Albertson; Michael Schivo; Amir A Zeki; Samuel Louie; Mark E Sutter; Mark Avdalovic; Andrew L Chan
Journal:  Drugs Aging       Date:  2013-07       Impact factor: 3.923

8.  Dose response relation to oral theophylline in severe chronic obstructive airways disease.

Authors:  H Chrystyn; B A Mulley; M D Peake
Journal:  BMJ       Date:  1988-12-10

9.  Progress in the management of childhood asthma.

Authors:  Pakit Vichyanond; Rattana Pensrichon; Suruthai Kurasirikul
Journal:  Asia Pac Allergy       Date:  2012-01-31

Review 10.  Differential pharmacokinetics of theophylline in elderly patients.

Authors:  Akihiro Ohnishi; Motokazu Kato; Jun Kojima; Hideki Ushiama; Maki Yoneko; Hiroyuki Kawai
Journal:  Drugs Aging       Date:  2003       Impact factor: 4.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.